Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig M Crews

Showing results (21-30 of 155) with videos related to

Pageof 16
Sort By:
Cell Chemical Biology|August 16, 2020
PROTACs: An Emerging Therapeutic Modality in Precision MedicineDhanusha A Nalawansha, Craig M Crews
Current Drug Targets|May 13, 2011
Natural product inhibitors of the ubiquitin-proteasome pathwayJohn S Schneekloth, Craig M Crews
Progress in Cell Cycle Research|November 5, 2003
Small-molecule inhibitors of the cell cycle: an overviewCraig M Crews, J Brad Shotwell
Cell|January 21, 2020
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological DiscoveryGeorge M Burslem, Craig M Crews
ACS Central Science|August 31, 2017
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug TargetPhilipp M Cromm, Craig M Crews
RSC Chemical Biology|January 7, 2026
Correction: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradationMichael J Bond, Craig M Crews
Chembiochem : a European Journal of Chemical Biology|November 9, 2004
Chemical approaches to controlling intracellular protein degradationJohn S Schneekloth, Craig M Crews
Journal of the American Society of Nephrology : JASN|January 2, 2009
Targeting cyst initiation in ADPKDStephanie J Leuenroth, Craig M Crews
The Journal of Biological Chemistry|December 17, 2003
A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidasesCathleen M Brdlik, Craig M Crews
Cancer Research|July 3, 2008
Triptolide-induced transcriptional arrest is associated with changes in nuclear substructureStephanie J Leuenroth, Craig M Crews
Pageof 16

Showing results (21-30 of 155) with videos related to

Sort By:
Pageof 16
Cell Chemical Biology|August 16, 2020
PROTACs: An Emerging Therapeutic Modality in Precision MedicineDhanusha A Nalawansha, Craig M Crews
Current Drug Targets|May 13, 2011
Natural product inhibitors of the ubiquitin-proteasome pathwayJohn S Schneekloth, Craig M Crews
Progress in Cell Cycle Research|November 5, 2003
Small-molecule inhibitors of the cell cycle: an overviewCraig M Crews, J Brad Shotwell
Cell|January 21, 2020
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological DiscoveryGeorge M Burslem, Craig M Crews
ACS Central Science|August 31, 2017
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug TargetPhilipp M Cromm, Craig M Crews
RSC Chemical Biology|January 7, 2026
Correction: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradationMichael J Bond, Craig M Crews
Chembiochem : a European Journal of Chemical Biology|November 9, 2004
Chemical approaches to controlling intracellular protein degradationJohn S Schneekloth, Craig M Crews
Journal of the American Society of Nephrology : JASN|January 2, 2009
Targeting cyst initiation in ADPKDStephanie J Leuenroth, Craig M Crews
The Journal of Biological Chemistry|December 17, 2003
A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidasesCathleen M Brdlik, Craig M Crews
Cancer Research|July 3, 2008
Triptolide-induced transcriptional arrest is associated with changes in nuclear substructureStephanie J Leuenroth, Craig M Crews
Pageof 16